MPM BIOVENTURES 2018, L.P. 4

Accession 0001209191-21-062983

CIK 0001689375other

View on SEC.gov Company Profile

Filed

Nov 3, 8:00 PM ET

Accepted

Nov 4, 5:38 PM ET

Size

19.3 KB

Accession

0001209191-21-062983

Insider Transaction Report

Form 4

Period: 2021-11-02

Entrada Therapeutics, Inc.TRDA

MPM BIOVENTURES 2018, L.P.

10% Owner

Transactions

Conversion
Common Stock
2021-11-02+3,816,760→ 3,816,760 total(indirect: See Footnote)
Purchase
Common Stock
2021-11-02$20.00/sh+100,000$2,000,000→ 4,425,784 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2021-11-02−3,683,241→ 0 total(indirect: See Footnote)
→ Common Stock (509,024 underlying)
Conversion
Common Stock
2021-11-02+509,024→ 4,325,784 total(indirect: See Footnote)
Conversion
Series A Preferred Stock
2021-11-02−27,617,675→ 0 total(indirect: See Footnote)
→ Common Stock (3,816,760 underlying)

MPM BioVentures 2018 LLC

10% Owner

Transactions

Conversion
Common Stock
2021-11-02+3,816,760→ 3,816,760 total(indirect: See Footnote)
Purchase
Common Stock
2021-11-02$20.00/sh+100,000$2,000,000→ 4,425,784 total(indirect: See Footnote)
Conversion
Series A Preferred Stock
2021-11-02−27,617,675→ 0 total(indirect: See Footnote)
→ Common Stock (3,816,760 underlying)
Conversion
Common Stock
2021-11-02+509,024→ 4,325,784 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2021-11-02−3,683,241→ 0 total(indirect: See Footnote)
→ Common Stock (509,024 underlying)

MPM BioVentures 2018 GP LLC

10% Owner

Transactions

Conversion
Common Stock
2021-11-02+509,024→ 4,325,784 total(indirect: See Footnote)
Purchase
Common Stock
2021-11-02$20.00/sh+100,000$2,000,000→ 4,425,784 total(indirect: See Footnote)
Conversion
Series A Preferred Stock
2021-11-02−27,617,675→ 0 total(indirect: See Footnote)
→ Common Stock (3,816,760 underlying)
Conversion
Common Stock
2021-11-02+3,816,760→ 3,816,760 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2021-11-02−3,683,241→ 0 total(indirect: See Footnote)
→ Common Stock (509,024 underlying)

Footnotes (8)

[F1]The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. .
[F2]Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
[F3]The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018.
[F4]Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
[F5]The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.
[F6]The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018.
[F7]The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018.
[F8]The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Entrada Therapeutics, Inc.

CIK 0001689375

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001729505

Filing Metadata

Form type: 4
Filed: Nov 3, 8:00 PM ET
Accepted: Nov 4, 5:38 PM ET
Size: 19.3 KB

View on SEC.gov